CITY THERAPEUTICS, INC. · Stock award · Stock Option (Right to Buy)

What does this filing report?

An SEC Form 4 filing for CITY THERAPEUTICS, INC. records a stock award involving Stock Option (Right to Buy) on October 15, 2026. The reported quantity was 22,649. The filing date is October 19, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Derivative terms

Underlying security

Common Stock

Underlying quantity

22,649

Conversion / exercise price

18

Exercise date

Not reported

Expiration date

October 14, 2036

Filing footnotes & remarks

F1

Each share of Series Seed convertible preferred stock, Series A convertible preferred stock and Series B convertible preferred stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-to-1.0983 basis at the option of the holder, and automatically converted into Common Stock upon the closing of the Issuer's initial public offering on October 19, 2026 without payment of consideration. The Preferred Stock had no expiration date.

F2

Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein, if any.

F3

The shares underlying this option vest in full upon the earlier of (i) October 15, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.